For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
As the global economy mends, the 2021 growth of Actovegin will have significant change from previous year. According to our (LP Information) latest study, the global Actovegin market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Actovegin market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Actovegin market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Actovegin market, reaching US$ million by the year 2028. As for the Europe Actovegin landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Actovegin players cover Nycomed (Takeda Pharmaceutical), Heilongjiang Jiangshi Pharmaceutical, Jilin Connell Pharmaceutical, and Harbin Shengtai Biopharmaceutical, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Actovegin market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
- Intravenous Drip
- Arterial Injection
- Intramuscular Injection
- Bladder Perfusion
- Oral Medicine
- Local Drug Delivery
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
- Adult
- Teenagers
- Infants and Young Children
- Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
- Nycomed (Takeda Pharmaceutical)
- Heilongjiang Jiangshi Pharmaceutical
- Jilin Connell Pharmaceutical
- Harbin Shengtai Biopharmaceutical
- Wuhan Renfu Pharmaceutical
- Hunan Wuzhoutong Pharmaceutical
- Heilongjiang Zhenbao Island Pharmaceutical
- Jinzhou Aohong Pharmaceutical Co. LTD
- Wuhan Hualong Biopharmaceutical